A study included 128 patients with T790M‐positive advanced NSCLC, who had progressed after prior TKIs treatment receiving osimertinib treatment, and the results demonstrated that median CNS PFS was not reached,18 indicating that osimertinib was a good choice for EGFR T790M‐positive NSCLC patients who failed TKIs treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.